Core Viewpoint - NLS Pharmaceutics Ltd. has undergone a significant transformation through a reverse stock split and a merger with Kadimastem Ltd., resulting in the formation of NewcelX Ltd. to enhance its focus on developing therapies for central nervous system disorders [1][2][5]. Group 1: Merger and Corporate Changes - The merger between NLS Pharmaceutics and Kadimastem was finalized on October 30, 2025, leading to the creation of NewcelX Ltd., which will trade on the Nasdaq Capital Market under the ticker symbol "NCEL" starting October 31, 2025 [2]. - The reverse stock split executed at a ratio of 10 for 1 is part of a broader strategy to strengthen the company's market position [1][3]. - The traded warrants of the company will be delisted following the merger [3]. Group 2: Financial Performance - Currently, NLSP's stock price is $0.762, reflecting an increase of 2.97% or $0.022, with a trading volume of 30.3 million shares on the NASDAQ exchange [4][5]. - The company's market capitalization stands at approximately $2.4 million, with the stock having traded between a low of $0.76 and a high of $0.83 on the day of reporting [4]. - Over the past year, the stock has reached a high of $47.4 and a low of $0.76 [4].

Core Viewpoint - NLS Pharmaceutics Ltd. is undergoing a significant transition involving a reverse stock split and a merger with Kadimastem Ltd. to enhance its market position and expand its capabilities in developing therapies for rare and complex central nervous system disorders [1][2][3] Group 1: Reverse Stock Split - A reverse stock split is scheduled for October 31, 2025, consolidating every 10 shares of NLSP into 1 share [2] - The current stock price is $0.74, reflecting a recent decrease of 29.52% [2] - The new CUSIP number for shares post-merger and reverse split will be H5835A109 [3] Group 2: Merger with Kadimastem Ltd. - The merger with Kadimastem Ltd. will result in a name change to NewcelX Ltd. and a new symbol "NCEL" on the Nasdaq Capital Market [2] - This merger aims to expand NLS Pharmaceutics' capabilities in its specialized field [3] Group 3: Market Performance - NLSP's stock has fluctuated between a low of $0.74 and a high of $0.94 today, with a yearly peak of $4.74 [3] - The company's market capitalization is approximately $2.34 million, with a trading volume of 1,409,410 shares [3]

Core Insights - NLS Pharmaceutics and Aexon Labs announced the expansion of their DOXA platform with the AEX-6xx series, focusing on small molecules that target arousal stability, cognition, and neuroprotection [1][4] - AEX-635, a lead compound, modulates MRP1, enhancing neuroprotective effects and improving CNS drug bioavailability, particularly in conditions like Parkinson's disease [1][3] Platform Expansion - The AEX-6xx program broadens the translational scope of the DOXA platform, integrating dual orexin receptor agonism with cathepsin H inhibition to address sleep-wake regulation and neuronal resilience [3][4] - The DOXA series aligns with the mission of NewCelX, the combined entity of NLS and Kadimastem, to innovate in neuroscience and cell therapy for neurological and metabolic disorders [4] Financial Position - NLS raised approximately $7 million in equity financing and secured a $25 million equity line of credit, strengthening its cash position for upcoming operations [5][6] - The financing is expected to support clinical programs and ensure the company is well-capitalized for at least the next 12 months [5] Preclinical Highlights - The DOXA platform shows up to 80% reduction in cataplexy and over 70% increase in wakefulness in narcolepsy models, demonstrating sustained efficacy without orexin receptor desensitization [9] - The platform exhibits robust neuroprotective activity under stress conditions, with potential applications in Type 1 Narcolepsy, ADHD, and neurodegenerative diseases [9][10] Intellectual Property - The AEX-6xx series is protected under international patent applications, advancing through national phases in key markets including the US, EU, and Japan [11] Strategic Next Steps - NLS and Aexon Labs are preparing for preclinical partnering discussions and plan to launch a unified brand identity under NewCelX, emphasizing their cross-continental model [12]

Core Insights - NLS Pharmaceutics Ltd. and Kadimastem Ltd. announced the continuation of the ITOL-102 cell therapy program for Type 1 Diabetes under the merged entity NewCelX Ltd. following their merger [1][3][4] Group 1: Company Overview - NLS Pharmaceutics is a biopharmaceutical company focused on innovative therapies for central nervous system disorders [5] - Kadimastem is a clinical-stage cell therapy company developing treatments for neurodegenerative diseases and diabetes [6] Group 2: ITOL-102 Program - The ITOL-102 program aims to develop a functional, stem-cell-derived pancreatic islet cell therapy to cure Type 1 Diabetes without lifelong immunosuppression [3] - The BIRD Foundation, which has invested over $300 million in joint projects since 1977, will continue to support the ITOL-102 program under NewCelX [2][4] Group 3: Strategic Focus - The merger allows NLS to leverage Kadimastem's advanced stem-cell platform, expanding its pipeline into regenerative and metabolic medicine [4]

Core Points - NLS Pharmaceutics Ltd. plans to execute a reverse share split at a ratio of 1-for-10, effective on October 30, 2025, in conjunction with a merger with Kadimastem Ltd. [1][2] - Following the reverse split, the company's common shares will trade under the new symbol "NCEL" starting October 31, 2025 [1][2] - The reverse split will also apply to preferred shares and preferred participation certificates at the same 1-for-10 ratio [3] Company Structure Post-Merger - After the reverse split and merger, the company's registered capital will consist of CHF 282,908.80, divided into 5,533,183 common shares and 124,993 preferred shares, among other capital structures [4] - The total outstanding common shares will be 4,558,378, with additional shares issuable upon the exercise of pre-funded warrants [6] Shareholder Impact - No fractional shares will be issued; instead, cash will be provided for any fractional shares resulting from the reverse split [5] - The reverse split will not affect shareholders' percentage ownership or voting power, aside from minor adjustments due to fractional shares [5]

Core Points - NLS Pharmaceutics Ltd. and Kadimastem Ltd. have received Nasdaq approval for the listing of the combined company's shares following the completion of their merger, set to close on October 30, 2025 [1][11] - The final exchange ratio for the merger is established at 7.06 NLS common shares for each Kadimastem ordinary share, which will adjust to 0.706 NLS common shares per Kadimastem ordinary share after a reverse share split [3] - The new entity will be named NewCelX Ltd. and will begin trading on the Nasdaq Capital Market under the ticker symbol "NCEL" starting October 31, 2025 [3] Company Information - NLS Pharmaceutics Ltd. is a Swiss-based biopharmaceutical company focused on developing innovative therapies for central nervous system disorders [5] - Kadimastem Ltd. is a clinical-stage cell therapy company that develops allogeneic, "off-the-shelf" cell products for neurodegenerative diseases and diabetes [6] Shareholder Information - Trading in Kadimastem's ordinary shares on the Tel Aviv Stock Exchange will be suspended until the shares are delisted upon merger completion, with final delisting scheduled for October 31, 2025 [2] - NewCelX common shares are expected to be deposited into Kadimastem shareholders' accounts by the end of the trading day on November 3, 2025, with trading expected to commence on November 4, 2025 [4]

Core Viewpoint - NLS Pharmaceutics Ltd. and Kadimastem Ltd. are set to merge, creating a new entity named NewcelX Ltd., with significant ownership stakes for Kadimastem shareholders [1][2][5]. Merger Details - The merger is expected to close on October 30, 2025, with trading under the new name starting on October 31, 2025, pending customary closing conditions [3]. - Kadimastem's ordinary shares will be delisted from the TASE on October 31, 2025, following the merger [4]. - The final exchange ratio was determined to be approximately 6.92 NLS shares for each Kadimastem share pre-reverse stock split, translating to about 0.62 NLS shares per Kadimastem share post-split [5][6]. Ownership Structure - Post-merger, Kadimastem shareholders will own approximately 84.4% of the combined company, while NLS shareholders will hold about 15.6% [5][8]. Clinical and Development Programs - NewCelX will advance its clinical programs, including AstroRx® for Amyotrophic Lateral Sclerosis (ALS) and IsletRx for insulin-dependent diabetes, following successful technology transfer and clinical manufacturing agreements [9].

Core Viewpoint - The merger between NLS Pharmaceutics Ltd. and Kadimastem Ltd. has been approved by NLS shareholders, paving the way for the formation of NewCelX Ltd., which will be listed on Nasdaq under the ticker "NCEL" [1][6][7]. Group 1: Merger Details - The merger will create a Nasdaq-listed company named NewCelX, with governance and capital structure approvals completed [2]. - Kadimastem shareholders will own 84.4% of the combined company, while NLS shareholders will own 15.6%, reflecting the relative value contributions of each party [5][6]. - The combined company will integrate Kadimastem's advanced cell therapy programs with NLS's expertise in CNS small-molecule therapies [2][7]. Group 2: Leadership and Governance - The leadership team will be headed by Ronen Twito as Executive Chairman and CEO, with Prof. Michel Revel serving as Chief Scientific Officer and Director [3][6]. - A new Board of Directors will be elected, and various committees will be newly constituted to enhance governance and execution [6]. Group 3: Clinical Programs and Pipeline - The merger will unite Kadimastem's clinical programs, including a Phase 2a ALS trial of AstroRx® and the IsletRx diabetes product candidate, with NLS's CNS therapies [7]. - The combined company aims to build a diversified biotechnology portfolio with the potential to deliver transformative therapies to patients worldwide [7].

Core Insights - The U.S. Securities and Exchange Commission (SEC) has declared effective the registration statement on Form F-4 for the merger between NLS Pharmaceutics Ltd. and Kadimastem Ltd., marking a significant milestone in the merger process [1][3][5] Company Overview - NLS Pharmaceutics Ltd. is a Swiss clinical-stage biopharmaceutical company focused on developing innovative therapies for central nervous system disorders [5][6] - Kadimastem Ltd. is an advanced clinical-stage cell therapy company developing treatments for neurodegenerative diseases and diabetes [6] Merger Details - The merger will create a new entity named NewCelX Ltd., which will be publicly traded on Nasdaq under the ticker "NCEL" [3][5] - This merger combines Kadimastem's cell therapy platforms with NLS's expertise in small-molecule therapies, aiming to enhance the therapeutic scope in CNS disorders and metabolic diseases [7] Clinical and Strategic Highlights - Kadimastem is preparing to initiate a Phase 2a clinical trial of AstroRx® for ALS treatment, with global trial site selection and regulatory preparations underway [7] - The IsletRx diabetes program, developed in collaboration with iTolerance, has received support from the BIRD Foundation following a successful Pre-IND meeting with the FDA [7] - The merger is expected to strengthen the global position of the combined company and provide access to U.S. capital markets [5][7]

Core Insights - Kadimastem has secured a patent in Hong Kong for its IsletRx technology, enhancing its global intellectual property (IP) portfolio, which already includes patents in Europe, the United States, and India [1][2][3] - The IsletRx platform aims to provide a scalable source of insulin-producing islet-like cells to address diabetes, a significant health challenge affecting millions globally [5][3] - The economic impact of diabetes in Hong Kong is substantial, with an estimated 706,000 adults affected, leading to lifetime healthcare costs averaging $125,000 per patient, translating to a potential economic burden of approximately $90 billion [3][4] Company Overview - Kadimastem Ltd. is a clinical-stage cell therapy company focused on developing allogeneic, "off-the-shelf" cell products for neurodegenerative diseases and diabetes [7] - NLS Pharmaceutics Ltd. is a Swiss-based biopharmaceutical company dedicated to innovative therapies for central nervous system disorders [6]